Efficacy of Sirolimus in Treating Tuberous Sclerosis and Lymphangioleiomyomatosis

Authors:
  • EPElahna Paul
    Elahna Paul
  • ETElizabeth Thiele
    Elizabeth Thiele

Abstract
Owing to their immunosuppressive and antiproliferative effects, sirolimus (also called rapamycin) and related drugs are being evaluated as part of many transplant immunosuppresion regimens, as well as for a plethora of medical conditions such as type 1 diabetes, macular degeneration, coronary artery disease, and metastatic or refractory cancers of the breast, prostate, lung, and liver, to name but a few.The effects of sirolimus are mediated by its inhibition of the curiously named cytoplasmic protein mammalian target of rapamycin (mTOR), a ubiquitous serine–threonine kinase that is intimately involved in the regulation of protein synthesis, cell growth, cytoskeletal organization, and other . . .

This publication has 11 references indexed in Scilit: